1. Introduction
1.1 Business Market Insights Research Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Hypothesis formulation:
- 3.2.2 Macro-economic factor analysis:
- 3.2.3 Developing base number:
- 3.2.4 Data Triangulation:
- 3.2.5 Country level data:
4. North America Point-of-Care Molecular Testing for Infectious Diseases Market Landscape
4.1 Market Overview
4.2 Porter's Five Forces Analysis
- 4.2.1 Bargaining Power of Suppliers
- 4.2.2 Bargaining Power of Buyers
- 4.2.3 Threat of New Entrants
- 4.2.4 Competitive Rivalry
- 4.2.5 Threat of Substitutes
4.3 Ecosystem Analysis
- 4.3.1 Raw Material Suppliers
- 4.3.2 Manufacturers
- 4.3.3 Distributors/Suppliers
- 4.3.4 End Users
5. North America Point-of-Care Molecular Testing for Infectious Diseases Market – Key Market Dynamics
5.1 Growth Drivers
- 5.1.1
- 5.1.2 surging prevalence of infectious diseases
- 5.1.3 Ramping preference for rapid diagnostic solutions
5.2 Market Opportunities
- 5.2.1 Increasing focus on R&D and funding in infectious diseases diagnostics
- 5.2.2 Development of new products
5.3 Future Trends
- 5.3.1
- 5.3.2 Diversified applications across oncology and chronic disease management
- 5.3.3 Rise in home and self-testing reflected to support market
- 5.3.4 Expanding healthcare infrastructure
5.4 Impact of Drivers and Restraints
6. North America Point-of-Care Molecular Testing for Infectious Diseases Market Regional Analysis
6.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Overview
6.2 North America Point-of-Care Molecular Testing for Infectious Diseases Market Revenue 2021-2031 (US$ Billion)
6.3 North America Point-of-Care Molecular Testing for Infectious Diseases Market Forecast Analysis
7. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Diseases
7.1 HIV Testing
- 7.1.1 Overview
- 7.1.2 HIV Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
7.2 Influenza Testing
- 7.2.1 Overview
- 7.2.2 Influenza Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
7.3 Sexually Transmitted Diseases Testing
- 7.3.1 Overview
- 7.3.2 Sexually Transmitted Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
7.4 Hepatitis C Virus Testing
- 7.4.1 Overview
- 7.4.2 Hepatitis C Virus Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
7.5 Tropical Diseases Testing
- 7.5.1 Overview
- 7.5.2 Tropical Diseases Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
7.6 Respiratory Infection Testing
- 7.6.1 Overview
- 7.6.2 Respiratory Infection Testing: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
7.7 Hospital Acquired Infections
- 7.7.1 Overview
- 7.7.2 Hospital Acquired Infections: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
7.8 Strep
- 7.8.1 Overview
- 7.8.2 Strep: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
8. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Technology
8.1 Lateral Flow Assay
- 8.1.1 Overview
- 8.1.2 Lateral Flow Assay: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
8.2 Dipsticks
- 8.2.1 Overview
- 8.2.2 Dipsticks: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
8.3 Microfluidics
- 8.3.1 Overview
- 8.3.2 Microfluidics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
8.4 Molecular Diagnostics
- 8.4.1 Overview
- 8.4.2 Molecular Diagnostics: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
8.5 Immunoassays
- 8.5.1 Overview
- 8.5.2 Immunoassays: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
8.6 Solid Phase
- 8.6.1 Overview
- 8.6.2 Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
9. North America Point-of-Care Molecular Testing for Infectious Diseases Market Analysis – by Prescription Testing
9.1 Prescription Based Testing
- 9.1.1 Overview
- 9.1.2 Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
9.2 OTC Testing
- 9.2.1 Overview
- 9.2.2 Solid Phase: North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
10. North America Point-of-Care Molecular Testing for Infectious Diseases Market – North America Analysis
10.1 North America
- 10.1.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Key
Country, 2024 and 2031 (%)
- 10.1.1.1 North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and
Forecast Analysis – by Country
- 10.1.1.1 US:
North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
- 10.1.1.1.1 US: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Diseases
- 10.1.1.1.2 US: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Technology
- 10.1.1.1.3 US: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Prescription Testing
- 10.1.1.2 Canada:
North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
- 10.1.1.2.1 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Diseases
- 10.1.1.2.2 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Technology
- 10.1.1.2.3 Canada: North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Prescription Testing
- 10.1.1.3 Mexico :
North America Point-of-Care Molecular Testing for Infectious Diseases Market – Revenue and Forecast to 2031 (US$ Billion)
- 10.1.1.3.1 Mexico : North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Diseases
- 10.1.1.3.2 Mexico : North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Technology
- 10.1.1.3.3 Mexico : North America Point-of-Care Molecular Testing for Infectious Diseases Market Breakdown, by Prescription Testing
11. Competitive Landscape
11.1 Heat Map Analysis
11.2 Company Positioning and Concentration
12. North America Point-of-Care Molecular Testing for Infectious Diseases Market Industry Landscape
12.1 Overview
12.2 Mergers and Acquisitions
12.3 Agreements, Collaborations, and Joint Ventures
12.4 New Product Launches
12.5 Expansions and Other Strategic Developments
13. Company Profiles
13.1 Abbott Laboratories
- 13.1.1 Key Facts
- 13.1.2 Business Description
- 13.1.3 Products and Services
- 13.1.4 Financial Overview
- 13.1.5 SWOT Analysis
- 13.1.6 Key Developments
13.2 Agilent Technologies Inc
- 13.2.1 Key Facts
- 13.2.2 Business Description
- 13.2.3 Products and Services
- 13.2.4 Financial Overview
- 13.2.5 SWOT Analysis
- 13.2.6 Key Developments
13.3 Becton Dickinson and Co
- 13.3.1 Key Facts
- 13.3.2 Business Description
- 13.3.3 Products and Services
- 13.3.4 Financial Overview
- 13.3.5 SWOT Analysis
- 13.3.6 Key Developments
13.4 Bio-Rad Laboratories Inc
- 13.4.1 Key Facts
- 13.4.2 Business Description
- 13.4.3 Products and Services
- 13.4.4 Financial Overview
- 13.4.5 SWOT Analysis
- 13.4.6 Key Developments
13.5 Cardinal Health Inc,
- 13.5.1 Key Facts
- 13.5.2 Business Description
- 13.5.3 Products and Services
- 13.5.4 Financial Overview
- 13.5.5 SWOT Analysis
- 13.5.6 Key Developments
13.6 Danaher Corp
- 13.6.1 Key Facts
- 13.6.2 Business Description
- 13.6.3 Products and Services
- 13.6.4 Financial Overview
- 13.6.5 SWOT Analysis
- 13.6.6 Key Developments
13.7 Cue Health Inc,
- 13.7.1 Key Facts
- 13.7.2 Business Description
- 13.7.3 Products and Services
- 13.7.4 Financial Overview
- 13.7.5 SWOT Analysis
- 13.7.6 Key Developments
13.8 QuidelOrtho Corp
- 13.8.1 Key Facts
- 13.8.2 Business Description
- 13.8.3 Products and Services
- 13.8.4 Financial Overview
- 13.8.5 SWOT Analysis
- 13.8.6 Key Developments
13.9 Thermo Fisher Scientific Inc
- 13.9.1 Key Facts
- 13.9.2 Business Description
- 13.9.3 Products and Services
- 13.9.4 Financial Overview
- 13.9.5 SWOT Analysis
- 13.9.6 Key Developments
13.10 F. Hoffmann-La Roche Ltd.
- 13.10.1 Key Facts
- 13.10.2 Business Description
- 13.10.3 Products and Services
- 13.10.4 Financial Overview
- 13.10.5 SWOT Analysis
- 13.10.6 Key Developments
14. Appendix
14.1 About Business Market Insights
Get Free Sample For North America Point-of-Care Molecular Testing for Infectious Diseases Market
